is semaglutide fda approved for obesity What's New in Treatment? Oral Obesity Drugs Edge Closer

Getting dressed has become fun again

GLP-1 , 45 (Meier ' -Diabetes 2004)

Visible fat loss on the scale: 4-12 weeks typically

Common side effects Most common during titration: mild nausea, fatigue, or digestive changes that typically resolve as the body adjusts to each dose increase

The primary evidence is the presence of antimitochondrial antibodies

But, if you have access to both, we would recommend the following: If your health would benefit from the higher percentage weight loss (15-20%) of Zepbound / tirzepatide, and you have not had a cardiac event, Zepbound offers modestly more weight loss with fewer side effects